Quality of life evaluation of chronic myeloid leukemia patients receiving long-term imatinib therapy from the EORTC QLQ-C30 questionnaire
Tạp chí Nghiên cứu Dược và Thông tin Thuốc · 25.04.2026 · 29
DOI: 10.59882/1859-364x/383 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tạp chí Nghiên cứu Dược và Thông tin Thuốc, online erschienen am 25.04.2026. Verfasst von Nguyen Thi Thu Cuc.
Abstract (Originalsprache)
To evaluate the quality of life and correlated factors in chronic myeloid leukemia patients undergoing long-term imatinib therapy. This was a cross-sectional study recruiting 383 chronic myeloid leukemia patients who presented criteria which included being at least 18 years old, positive BCR-ABL gene and undergoing IM therapy for at least 6 months. Quality of life was evaluated with the EORTC QLQ-C30 questionnaire and defined by EORTC group guidelines. Descriptive statistics, one-way ANOVA and multivariable linear regression test were used. P-value
Zitieren
APA
Cuc, N. T. T. (2026). Quality of life evaluation of chronic myeloid leukemia patients receiving long-term imatinib therapy from the EORTC QLQ-C30 questionnaire. Tạp chí Nghiên cứu Dược và Thông tin Thuốc, 29. https://doi.org/10.59882/1859-364x/383
Vancouver
Cuc NTT. Quality of life evaluation of chronic myeloid leukemia patients receiving long-term imatinib therapy from the EORTC QLQ-C30 questionnaire. Tạp chí Nghiên cứu Dược và Thông tin Thuốc. 2026;29. doi:10.59882/1859-364x/383
BibTeX
@article{Cuc2026,
author = {Cuc, Nguyen Thi Thu},
title = {Quality of life evaluation of chronic myeloid leukemia patients receiving long-term imatinib therapy from the EORTC QLQ-C30 questionnaire},
journal = {Tạp chí Nghiên cứu Dược và Thông tin Thuốc},
year = {2026},
volume = {29},
doi = {10.59882/1859-364x/383}
}
EUVIMED